36 diagnostic codes were added to private reimbursement schedule in England in August

The Clinical Coding and Schedule Development (CCSD) develops and maintains procedural and diagnostics nomenclature for private payers in England. Once codes are added to the Schedule, a private insurance company can develop reimbursement tariff for these procedures and tests.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in August:

• Thermography (MI047)
• Mole mapping (MI048)
• Hyperferritinemia - cataract testing (OP041)
• Mycobacteria genotype ID (5025T)
• Hereditary neuropathy with liability to pressure palsies (5026B)
• Minimal residual disease (5027B)
• Urine pheuma antibody (5028U)
• Ferroportin SLC40A1 gene sequencing (5029B)
• Thromboelastometry (5030B)
• O(6)-Methylguanine-DNA methyltransferase (MGMT) gene (5031T)
• 18 Gene panel glycogon storage (5032B)
• Zinc transport 8 (5033B)
• RH5 (5034B)
• Calcium corrected (5035B)
• Otoblot-inner ear antigen (5036B)
• PROP profile (5037B)
• AMA autoantibodies (5038B)
• SMA autoantibodies (5039B)
• Neurone specific enolase (NSE) (5040B)
• C. difficile ribotyping (5041F)
• C. difficile PCR (5042F)
• Faecal multiplex PCR (5043F)
• Staphylococcus PVL testing (5044S)
• SKAB: skin antibodies (5045B)
• Measles, mumps and rubella antibodies (5046B)
• ANTI-AMPA 1/2 antibodies (5047B)
• MPL mutation (5048B)
• Serum free light chains (5049B)
• T cell clonality (5050M)
• Beta D glucan (5051T)
• C-MYC FISH (5052M)
• CYP21A2 gene sequencing (5053B)
• G6PD gene deficiency gene test (5054B)
• Hydrocortisone test (5055B)
• Abelson murine leukaemia oncogene testing (5056B)
• Mismatch repair protein MMR (5057T)

See full information here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.